Total Clinical Trial Management Successfully Completes Trial 5 Weeks Ahead of Projections

Share Article

Total Clinical Trial Management, an emerging CRO based in Dallas has delivered Texas-sized results in its most recent program

Total Clinical Trial Management
We attribute much of the success of the program to the unique approach that TCTM took in collaborating with the research sites.

Total Clinical Trial Management (TCTM) is a full service CRO created on the founding principle that relationships between research sites and the CRO is a critical element in ensuring successful study completion. TCTM’s proprietary TotalTouch Site Advantage process has proven to dramatically increase study timelines and deliver results.

The Phase 3 program used a once daily topical patch in the treatment of acute low back pain versus placebo. MEDRx Co., Ltd US subsidiary, IL Pharma and TCTM’s planned enrollment projections were 224 patients within 6 months at 10 research site locations. The study ultimately completed 5 weeks ahead of the aggressive timeline with 232 patients enrolled in 5 months at 7 sites. President and CEO of IL Pharma, Yuji Kuwabara stated “We attribute much of the success of the program to the unique approach that TCTM took in collaborating with the research sites.”

Total Clinical Trial Management has a wide range of therapeutic expertise with recent areas of focus including pain, orthopedic injury, dermatology, over-the-counter (OTC), generic and cosmetic studies. Visit our website, http://www.totalCRO.com to learn more about TCTM and the site-focused model for successful study management.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Andrew Kimball
Visit website